RxDoctor Payments Data

Stephanie Coleman

Family · Indianapolis, INNPI 1164128815

Payments from drug & device makers

$270in general payments, 2019–2025

Across 15 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$84
  • Novo Nordisk$53
  • Lilly USA, LLC$49
  • AstraZeneca$34
  • Watermark Medical, Inc.$19
  • GSK$18
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$270100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie4$84
Novo Nordisk3$53
Lilly USA, LLC3$49
AstraZeneca2$34
Watermark Medical, Inc.1$19
GSK1$18
Exact Sciences1$14

How this compares

$270 in reported general payments places this provider in the 40th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$52,960
Medicare patients
157
Services billed
830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$83,719
MounjaroTirzepatide29$31,121
JardianceEmpagliflozin27$27,722
RybelsusSemaglutide12$22,157
EliquisApixaban19$21,661
TradjentaLinagliptin14$20,269
Tresiba Flextouch U-100Insulin Degludec22$16,006
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,305
Humalog Kwikpen U-200Insulin Lispro17$12,913
JanuviaSitagliptin Phosphate19$11,771
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$8,648
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,994
Fiasp FlextouchInsulin Aspart (Niacinamide)11$6,415
Albuterol Sulfate HfaAlbuterol Sulfate121$2,432
Diclofenac Sodium58$2,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$53$105,87691 claims
Lilly USA, LLCMounjaro$49$31,12129 claims
GSKTrelegy Ellipta$18$15,30524 claims
AstraZenecaBreztri Aerosphere$34$6,99411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 4,392 family providers in Indiana.

Other family in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →